Cardiovascular benefits of semaglutide: a systematic review and meta-analysis of randomized controlled trials
Semaglutide effectively reduces the risk of MACE and modestly improves cardiovascular mortality rates and nonfatal myocardial infarction, without significantly affecting nonfatal stroke incidence and hospitalizations (for angina and heart failure). While it lowers the occurrence of serious adverse events, it also increases the likelihood of discontinuing treatment.
Authors
- Ida Mohammadi (ORCID: https://orcid.org/0000-0002-0662-0329)
- Samin Sadraei (ORCID: https://orcid.org/0000-0003-3988-7449)
- Aryan Aarabi (ORCID: https://orcid.org/0000-0002-0545-4891)
- Amir Ghaffari Jolfayi (ORCID: https://orcid.org/0000-0002-9223-5565)
- Shahryar Rajai Firouzabadi (ORCID: https://orcid.org/0000-0001-6511-4103)
- Mohammadreza Alinejadfard
Institutions
- Shahid Beheshti University of Medical Sciences (IR)
Publication Details
- Journal
- BMC Cardiovascular Disorders
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1186/s12872-025-05278-3
- Citations
- 3
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 3.88